Market Overview

Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints

Share:
Related RIGL
Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know
Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP
Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)

Shares of Rigel Pharma (NASDAQ: RIGL) have traded down around 12-13 percent throughout Monday morning's trading session following some concerning data from a trial of its R343. Rigel shares have bounced sharply from the pre-market low under $2.50.

Analyst Marko Kozul at Leerink Swann, a firm which specializes in the Pharma group, said he was surprised by the failure of the R343 trial to miss the primary and secondary endpoints.

Although the analyst was caught off guard, he cited low expectations for the remaining three catalysts over the near term for his reiterated Outperform rating. Kozul adjusted his price target on Rigel Pharma lower from $7 previously to $5.

With Rigel shares down to around $3.18 at last check, Kozul's new, lowered price target still represents potential upside of nearly 60 percent.

Latest Ratings for RIGL

DateFirmActionFromTo
Apr 2016JP MorganUpgradesNeutralOverweight
Mar 2014JefferiesMaintainsBuy
Jun 2013JefferiesMaintainsBuy

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration FDA Analyst Ratings Movers

 

Related Articles (RIGL)

View Comments and Join the Discussion!